{"schema_version":"secwatch.filing_event.v1","accession":"0001041024-25-000009","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.177980+00:00","generated_at":"2026-05-17T12:43:47.652448+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M","bullets":["Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.","Net loss $1.5M vs net income $0.3M in Q2 2024; Adjusted EBITDA -$0.2M vs $1.4M year ago.","Cash & investments increased to $18.4M, supported by $1.8M operating cash flow.","Reaffirmed 2025 guidance: net sales $65-70M, gross margin 16-18%, Adj EBITDA -$0.5M to $0.5M.","Secured multi-year supply agreements with Innovative Renal Care (3-yr) and other providers; >80% customers under long-term contracts."],"urls":{"canonical":"https://secwatch.observer/filing/0001041024-25-000009","json":"https://secwatch.observer/filing/0001041024-25-000009.json","markdown":"https://secwatch.observer/filing/0001041024-25-000009.md","text":"https://secwatch.observer/filing/0001041024-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000104102425000009/0001041024-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000104102425000009/rmti-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:43:47.652448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}